Provided by Tiger Trade Technology Pte. Ltd.

Apogee Therapeutics

72.59
-2.0900-2.80%
Volume:262.56K
Turnover:19.05M
Market Cap:5.04B
PE:-17.22
High:74.17
Open:73.64
Low:71.35
Close:74.68
52wk High:84.56
52wk Low:26.20
Shares:69.49M
Float Shares:52.45M
Volume Ratio:0.54
T/O Rate:0.50%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-4.2155
EPS(LYR):-4.2155
ROE:-31.57%
ROA:-21.11%
PB:5.58
PE(LYR):-17.22

Loading ...

Apogee Therapeutics CEO Michael Henderson Reports Sale of Common Shares

Reuters
·
Dec 13, 2025

Apogee Therapeutics Inc : Deutsche Bank Initiates Coverage With Buy Rating and Target Price $103

THOMSON REUTERS
·
Dec 10, 2025

U.S. RESEARCH ROUNDUP-JP Morgan, Pepsico, Pfizer

Reuters
·
Dec 10, 2025

Apogee Therapeutics Chief Medical Officer Carl Dambkowski Reports Sale of Common Shares

Reuters
·
Dec 06, 2025

Apogee Therapeutics CFO Jane Henderson Reports Disposal of Common Shares

Reuters
·
Dec 06, 2025

Does Positive APG333 Data and $345 Million Raise Redefine the Bull Case for Apogee Therapeutics (APGE)?

Simply Wall St.
·
Dec 03, 2025

Apogee Therapeutics CFO Jane Henderson Reports Disposal of Common Shares

Reuters
·
Nov 29, 2025

Positive Early APG333 Data Could Be a Game Changer for Apogee Therapeutics (APGE)

Simply Wall St.
·
Nov 23, 2025

Apogee Therapeutics CEO Michael Henderson Reports Disposal of Common Shares

Reuters
·
Nov 14, 2025

Apogee Therapeutics Reports Q3 2025 Financial Progress

TIPRANKS
·
Nov 12, 2025

RBC Capital Sticks to Their Buy Rating for Apogee Therapeutics (APGE)

TIPRANKS
·
Nov 12, 2025

Stock Track | Apogee Therapeutics Soars 5.28% Following Mizuho Securities' Bullish Stance

Stock Track
·
Nov 11, 2025

Stock Track | Apogee Therapeutics Soars 5.28% Following Mizuho Securities' Buy Rating and $105 Price Target

Stock Track
·
Nov 11, 2025

Mizuho Securities Sticks to Their Buy Rating for Apogee Therapeutics (APGE)

TIPRANKS
·
Nov 11, 2025

Apogee Therapeutics Reports Positive Interim Results for APG333 Antibody

MT Newswires Live
·
Nov 10, 2025

Positive Buy Rating for Apogee Therapeutics Driven by Promising Clinical Trials and Strategic Advancements

TIPRANKS
·
Nov 10, 2025

Apogee Therapeutics Announces Positive Phase 1 Results

TIPRANKS
·
Nov 10, 2025

Earnings Flash (APGE) Apogee Therapeutics Posts Q3 Net Loss $1.11, vs. FactSet Est of $1.15 Loss

MT Newswires Live
·
Nov 10, 2025

Update: Apogee Therapeutics Q3 EPS $(1.11) Beats $(1.20) Estimate

Benzinga
·
Nov 10, 2025

BRIEF-Apogee Therapeutics Provides Pipeline Progress

Reuters
·
Nov 10, 2025